Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.
J-J
JJ
Kiladjian
A
A
Massé
B
B
Cassinat
H
H
Mokrani
I
I
Teyssandier
J-P
JP
le Couédic
N
N
Cambier
C
C
Almire
E
E
Pronier
N
N
Casadevall
W
W
Vainchenker
C
C
Chomienne
F
F
Delhommeau
D004268:DNA-Binding Proteins / Q000235:genetics*; D049308:Dioxygenases; D015672:Erythroid Precursor Cells / Q000166:cytology / Q000201:enzymology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000235:genetics*; D009154:Mutation; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D011994:Recombinant Proteins
D004268:DNA-Binding Proteins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011518:Proto-Oncogene Proteins; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D049308:Dioxygenases; C541081:TET2 protein, human; D053614:Janus Kinase 2; C100416:peginterferon alfa-2a